Publication:
Whole Blood versus Red Cells and Plasma for Exchange Transfusion in ABO Haemolytic Disease

dc.authorwosidAydin, Murat/Aaa-6922-2019
dc.authorwosidErdem, Gökhan/Kly-5466-2024
dc.authorwosidGursoy, Tugba/Ago-5295-2022
dc.authorwosidYigit, Sinan/Kgm-9179-2024
dc.contributor.authorYigit, S
dc.contributor.authorGursoy, T
dc.contributor.authorKanra, T
dc.contributor.authorAydin, M
dc.contributor.authorErdem, G
dc.contributor.authorTekinalp, G
dc.contributor.authorYurdakok, M
dc.contributor.authorIDGursoy, Tugba/0000-0002-6084-4067
dc.date.accessioned2025-12-11T01:02:41Z
dc.date.issued2005
dc.departmentOndokuz Mayıs Üniversitesien_US
dc.department-tempHacettepe Univ, Fac Med, Neonatol Unit, TR-06100 Ankara, Turkey; Hacettepe Univ, Fac Med, Blood Unit, TR-06100 Ankara, Turkey; Ondokuzmayis Univ Fac Med, Ankara, Turkeyen_US
dc.descriptionGursoy, Tugba/0000-0002-6084-4067;en_US
dc.description.abstractRecords of 381 neonates who underwent exchange transfusion (ET) due to ABO haemolytic disease at the Division of Neonatology of Hacettepe University, Ankara, Turkey, between January 1977 and December 2003 were reviewed. Records were kept for the type of blood used in ET, the number of ETs for each infant, adverse event attributable to ET and bilirubin levels before, and 4 and 8 h after each ET. Of 381 infants, 300 were transfused with whole blood, whereas 81 infants were transfused with 0 red cells suspended in A or B plasma. The reexchange rate was higher in the whole blood group, compared with the erythrocyte and plasma group. Use of erythrocyte and plasma provided 30% reduction in the number of ETs per patient. Eight hours after the first ET, mean bilirubin levels were 84% of the pre-exchange values in the whole blood group and 73% of the pre-exchange values in the erythrocyte and plasma group (P = 0.001). As the use of O group red cells re-suspended in AB plasma decreased the re-exchange risk compared with O group whole blood, we suggest the use of O red cells re-suspended in AB plasma for the ET in cases of ABO haemolytic disease.en_US
dc.description.woscitationindexScience Citation Index Expanded
dc.identifier.doi10.1111/j.0958-7578.2005.00593.x
dc.identifier.endpage318en_US
dc.identifier.issn0958-7578
dc.identifier.issn1365-3148
dc.identifier.issue4en_US
dc.identifier.pmid16101809
dc.identifier.scopusqualityQ3
dc.identifier.startpage313en_US
dc.identifier.urihttps://doi.org/10.1111/j.0958-7578.2005.00593.x
dc.identifier.urihttps://hdl.handle.net/20.500.12712/40900
dc.identifier.volume15en_US
dc.identifier.wosWOS:000231700800008
dc.identifier.wosqualityQ3
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofTransfusion Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectABO Incompatibilityen_US
dc.subjectErythrocyte and Plasmaen_US
dc.subjectExchange Transfusionen_US
dc.subjectHaemolytic Disease of the Newbornen_US
dc.subjectNewbornen_US
dc.subjectWhole Blooden_US
dc.titleWhole Blood versus Red Cells and Plasma for Exchange Transfusion in ABO Haemolytic Diseaseen_US
dc.typeArticleen_US
dspace.entity.typePublication

Files